Reading PRCT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PRCT free→Reading PRCT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PRCT free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-15
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been fairly steady, and it has a capital-friendly stance. Risk is elevated, and the sector backdrop is a headwind, with performance compared to sector peers being typical. Peer multiples imply a price about 6% above where it trades (it looks cheap on this basis); the read is fair, but weakening. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $23.22. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $23 PRCT trades at 4× p/s — 1.5× the 3× p/s peer median. The market is re-rating it beyond its own range; our $25 fair value is low-confidence here. Analysts: $29–$35. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 7% below a flat-multiple fair value, below our forecast of about 41%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 10.02x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
3 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.45 → $-0.46 (-0.6% / 30d). 0 raised, 2 cut, 10 covering analysts.
0 upgrades, 1 downgrade / 30d, 0 maintained. 54% of analysts rate Buy.
1 PT revisions / 30d. Avg target -0.3% above current price.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$255.
How much price usually moves either way.
On a bad day, this stock has moved -$546.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,419.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Valuation label changed from 'full' to 'fair'.
As of June 15, 2026, the valuation dimension changed and rose, with the valuation label shifting from "full" to "fair." The risk dimension also fell, indicating a decrease in overall risk. The sector backdrop remains a headwind, which has not changed. The company continues to show loss-making earnings quality, and recent financial performance is described as weak.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If sector growth picks up, it may help PROCEPT BioRobotics. This could improve its market position.
Confirms:Sector revenue growth is speeding up to about 10% each year.
Disproves:Sector revenue growth is slowing down to less than 5% each year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for PRCT yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition On April 29, 2026 , PROCEPT BioRobotics Corporation (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2026 . The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
$29.00 – $35.00 (median $32.00) · 4 analysts · as of 2026-06-11
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
PRCT PROCEPT BioRobotics Corp. | Typical Show detailsSector percentile: 44 of 100 | fair | elevated |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 94 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The company aims to achieve a revenue range of $390 million to $410 million for the full year 2026.
Stated in 3 of last 3 quarters. Revenue grew from $682.36M in 2024 to $831.32M in 2026-Q1, indicating progress towards the $390M-$410M full-year target. The trajectory shows delivering growth, aligning with management's guidance.
“The Company continues to expect revenue for the full year 2026 to be in the range of $390 million to $410 million.”
“we are resetting our 2026 guidance to $390 to $410 million, representing annual growth of 27% to 33%”
“The Company projects revenue for the full year 2026 to be in the range of $410 to $430 million”
The company aims to maintain a gross margin of approximately 65% for the full year 2026.
Stated in 2 of last 2 quarters. Gross profit was $53.95M in 2026-Q1, supporting the target of maintaining a 65% gross margin for the year. The trajectory is consistent with management's expectations.
The company aims to achieve an adjusted EBITDA loss in the range of $17 million to $30 million for the full year 2026.
Stated in 2 of last 2 quarters. Operating income was -$32.61M in 2026-Q1, indicating a challenging path towards the adjusted EBITDA loss target of $17M-$30M for 2026. The trajectory shows limited progress so far.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 5, 2026, the board of directors (the “Board”) of PROCEPT BioRobotics Corporation (the “Company”) approved (i) an increase in the size of the Board from eight members to nine members, (ii) appointed Mr. Daniel Puckett as a new member of the Board to fill the resulting vacancy, and (iii) appointed Mr. Puckett as a member of the Audit Committ…
Results of Operations and Financial Condition On February 25, 2026, PROCEPT BioRobotics Corporation (the "Company") issued a press release announcing its financial results for the quarter ended December 31, 2025 . The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Secur…
Results of Operations and Financial Condition On November 4, 2025 , PROCEPT BioRobotics Corporation (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2025 . The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Secu…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Amended Change of Control and Severance Agreements As part of an ongoing evaluation of its executive compensation programs, the Compensation Committee of the Board of Directors of PROCEPT BioRobotics Corporation (the "Company") reviewed the existing form of Change of Control and Severance Agreement for its executive officers below the chief executi…
“The Company continues to expect full year 2026 gross margin to be approximately 65%.”
“The Company expects full year 2025 gross margin to be approximately 64.5%.”
“The Company continues to expect full year 2026 adjusted EBITDA* loss to be in the range of $30 million to $17 million.”
“The Company projects full year 2025 Adjusted EBITDA loss to be approximately ($35.0) million.”